CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment

Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer

Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R. (2017) · Nature · doi:10.1038/nature22341 · Cited by 2,639 · see citing works

CD44: From adhesion molecules to signalling regulators

Ponta, H., Sherman, L. S., & Herrlich, P. A. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1004 · Cited by 2,393 · see citing works

Drugging the undruggable RAS: Mission Possible?

Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · see citing works

Essential role for oncogenic Ras in tumour maintenance

Chin, L., Tam, A., Pomerantz, J. H., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 928 · see citing works

Dragging ras back in the ring

Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795 · see citing works

Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice

Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galbán, S., Galbán, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & Pasca di Magliano, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59227 · Cited by 770 · see citing works

Chitosan nanoparticles as delivery systems for doxorubicin

Janes, K. A., Fresneau, M. P., Marazuela, A., Fabra, À., & Alonso, M. J. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00294-2 · Cited by 721 · see citing works

Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine

Mattheolabakis, G., Milane, L., Singh, A., & Amiji, M. M. (2015) · Journal of Drug Targeting · doi:10.3109/1061186x.2015.1052072 · Cited by 597 · see citing works

Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer

Deng, X., Cao, M., Zhang, J., Hu, K., Yin, Z., Zhou, Z., Xiao, X., Yang, Y., Sheng, W., Wu, Y. F., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.02.006 · Cited by 515 · see citing works

Hyaluronan–CD44 interactions as potential targets for cancer therapy

Misra, S., Heldin, P., Hascall, V. C., Karamanos, N. K., Skandalis, S. S., Markwald, R. R., & Ghatak, S. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08071.x · Cited by 494 · see citing works

The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan.

Culty, M., Nguyen, H., & Underhill, C. B. (1992) · The Journal of Cell Biology · doi:10.1083/jcb.116.4.1055 · Cited by 399 · see citing works

The depolymerization of chitosan: effects on physicochemical and biological properties

Mao, S., Shuai, X., Unger, F. T., Simon, M. W., Bi, D., & Kissel, T. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.05.019 · Cited by 376 · see citing works

Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors

Ganesh, S., Iyer, A. K., Morrissey, D. V., & Amiji, M. M. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.077 · Cited by 361 · see citing works

Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells

Yu, M., Jambhrunkar, S., Thorn, P., Chen, J., Gu, W., & Yu, C. (2012) · Nanoscale · doi:10.1039/c2nr32145a · Cited by 336 · see citing works

A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

Collisson, E. A., Trejo, C. L., Silva, J. M., Gu, S., Korkola, J. E., Heiser, L. M., Charles, R., Rabinovich, B. A., Hann, B. C., Dankort, D. L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0347 · Cited by 320 · see citing works

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

Hatzivassiliou, G., Haling, J. R., Chen, H., Song, K. W., Price, S., Heald, R. A., Hewitt, J. F. M., Zak, M., Peck, A., Orr, C., et al. (2013) · Nature · doi:10.1038/nature12441 · Cited by 317 · see citing works

c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma

Blasco, R. B., Francoz, S., Santamaría, D., Cañamero, M., Dubus, P., Charron, J., Baccarini, M., & Barbacid, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.002 · Cited by 302 · see citing works

Mutant KRAS is a druggable target for pancreatic cancer

Zorde Khvalevsky, E., Gabai, R., Rachmut, I. H., Horwitz, E., Brunschwig, Z., Orbach, A., Shemi, A., Golan, T., Domb, A. J., Yavin, E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314307110 · Cited by 295 · see citing works

Design considerations for nanotherapeutics in oncology

Stylianopoulos, T., & Jain, R. K. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.07.015 · Cited by 283 · see citing works

Development of Farnesyl Transferase Inhibitors: A Review

Appels, N. M. G. M., Beijnen, J. H., & Schellens, J. H. M. (2005) · The Oncologist · doi:10.1634/theoncologist.10-8-565 · Cited by 272 · see citing works

A Hyaluronic Acid−Taxol Antitumor Bioconjugate Targeted to Cancer Cells

Luo, Y., Ziebell, M. R., & Prestwich, G. D. (2000) · Biomacromolecules · doi:10.1021/bm000283n · Cited by 262 · see citing works

The antimicrobial polymer PHMB enters cells and selectively condenses bacterial chromosomes

Chindera, K., Mahato, M., Sharma, A. K., Horsley, H., Kloc-Muniak, K., Kamaruzzaman, N. F., Kumar, S., McFarlane, A., Stach, J., Bentin, T., et al. (2016) · Scientific Reports · doi:10.1038/srep23121 · Cited by 253 · see citing works

The CD44‐Mediated Uptake of Hyaluronic Acid‐Based Carriers in Macrophages

Rosa, J. M. R. D. L., Tirella, A., Gennari, A., Stratford, I. J., & Tirelli, N. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201601012 · Cited by 213 · see citing works

Roles and targeting of the HAS/hyaluronan/CD44 molecular system in cancer

Karousou, E. G., Misra, S., Ghatak, S., Dobra, K., Götte, M., Vigetti, D., Passi, A. G., Karamanos, N. K., & Skandalis, S. S. (2016) · Matrix Biology · doi:10.1016/j.matbio.2016.10.001 · Cited by 202 · see citing works

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS

Ross, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal5253 · Cited by 177 · see citing works

Hyaluronic acid-conjugated graphene oxide/photosensitizer nanohybrids for cancer targeted photodynamic therapy

Li, F., Park, S., Ling, D., et al. (2013) · Journal of Materials Chemistry B · doi:10.1039/c3tb00506b · Cited by 175 · see citing works

Targeted Delivery of Doxorubicin by HPMA Copolymer-Hyaluronan Bioconjugates

Luo, Y., Bernshaw, N. J., Lu, Z., Kopec̆ek, J., & Prestwich, G. D. (2002) · Pharmaceutical Research · doi:10.1023/a:1015170907274 · Cited by 172 · see citing works

Lipoplexes Targeting the CD44 Hyaluronic Acid Receptor for Efficient Transfection of Breast Cancer Cells

Surace, C., Arpicco, S., Dufaÿ-Wojcicki, A., et al. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800215d · Cited by 160 · see citing works

Hyaluronic Acid- Paclitaxel: Antitumor Efficacy against CD44(+) Human Ovarian Carcinoma Xenografts

Auzenne, E. J., Ghosh, S. C., Khodadadian, M., Rivera, B., Farquhar, D., Price, R. E., Ravoori, M. K., Kundra, V., Freedman, R. S., & Klostergaard, J. (2007) · Neoplasia · doi:10.1593/neo.07229 · Cited by 159 · see citing works

Chitosan/Hyaluronic Acid Nanoparticles: Rational Design Revisited for RNA Delivery

Lallana, E., Rosa, J. M. R. D. L., Tirella, A., Pelliccia, M., Gennari, A., Stratford, I. J., Puri, S., Ashford, M. B., & Tirelli, N. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00320 · Cited by 146 · see citing works

The importance of being K-Ras

Ellis, C. A., & Clark, G. (2000) · Cellular Signalling · doi:10.1016/s0898-6568(00)00084-x · Cited by 145 · see citing works

Hyaluronic acid (HA) presentation as a tool to modulate and control the receptor-mediated uptake of HA-coated nanoparticles

Almalik, A., Karimi, S., Ouasti, S., Donno, R., Wandrey, C., Day, P. J., & Tirelli, N. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.03.065 · Cited by 138 · see citing works

Targeting Mutant KRAS for Anticancer Therapeutics: A Review of Novel Small Molecule Modulators

Wang, Y., Kaiser, C. E., Frett, B., & Li, H. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3017706 · Cited by 121 · see citing works

Paclitaxel-Hyaluronic Acid for Intravesical Therapy of Bacillus Calmette-Guérin Refractory Carcinoma In Situ of the Bladder: Results of a Phase I Study

Bassi, P. F., Volpe, A., D’Agostino, D., et al. (2010) · The Journal of Urology · doi:10.1016/j.juro.2010.09.073 · Cited by 104 · see citing works

Hyaluronic acid-conjugated mesoporous silica nanoparticles: excellent colloidal dispersity in physiological fluids and targeting efficacy

Ma, M., Chen, H., Chen, Y., Zhang, K., Wang, X., Cui, X., & Shi, J. (2012) · Journal of Materials Chemistry · doi:10.1039/c2jm15489g · Cited by 93 · see citing works

The status and role of ErbB receptors in human cancer

Überall, I., Kolář, Z., Trojanec, R., Berkovcová, J., & Hajdúch, M. (2008) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2007.12.002 · Cited by 92 · see citing works

Hyaluronic acid/Chitosan nanoparticles as delivery vehicles for VEGF and PDGF-BB

Parajó, Y., d’Angelo, I., Welle, A., et al. (2010) · Drug Delivery · doi:10.3109/10717544.2010.509357 · Cited by 89 · see citing works

CD44 Expression in Colorectal Adenomas Is an Early Event Occurring Prior to K-ras and p53 Gene Mutation

Kim, H., Yang, X., Rosada, C., et al. (1994) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1994.1199 · Cited by 81 · see citing works

Hyaluronan, CD44, and Cyclooxygenase-2 in Colon Cancer

Misra, S., Hascall, V., Berger, F. G., Markwald, R. R., & Ghatak, S. (2008) · Connective Tissue Research · doi:10.1080/03008200802143356 · Cited by 63 · see citing works

Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy

Alves, S., Castro, L., Fernandes, M. S., Francisco, R., Castro, P. J. T. D., Priault, M., Chaves, S. R., Moyer, M. P., Oliveíra, C., Seruca, R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5021 · Cited by 60 · see citing works

HA ‐ C oated Chitosan Nanoparticles for CD 44‐ M ediated Nucleic Acid Delivery

Almalik, A., Day, P. J., & Tirelli, N. (2013) · Macromolecular Bioscience · doi:10.1002/mabi.201300302 · Cited by 58 · see citing works

CD44 promotes Kras-dependent lung adenocarcinoma

Zhao, P., Damerow, M. S., Stern, P., et al. (2012) · Oncogene · doi:10.1038/onc.2012.542 · Cited by 58 · see citing works

CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients

Birzele, F., Voß, E., Nopora, A., Honold, K., Heil, F., Lohmann, S., Verheul, H. M. W., Tourneau, C. L., Delord, J., van Herpen, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2141 · Cited by 56 · see citing works

K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives

Asati, V., Mahapatra, D. K., & Bharti, S. K. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.049 · Cited by 55 · see citing works

Knockdown of mutant K-ras expression by adenovirus-mediated siRNA inhibits the in vitro and in vivo growth of lung cancer cells

Zhang, Z., Jiang, G., Yang, F., & Wang, J. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.11.3297 · Cited by 54 · see citing works

Colorectal tumor 3Din vitromodels: advantages of biofabrication for the recapitulation of early stages of tumour development

Rosa, J. M. R. D. L., Wubetu, J., Tirelli, N., & Tirella, A. (2018) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/aac1c9 · Cited by 47 · see citing works

Receptor‐Targeted Drug Delivery and the (Many) Problems We Know of: The Case of CD44 and Hyaluronic Acid

Rosa, J. M. R. D. L., Tirella, A., & Tirelli, N. (2018) · Advanced Biosystems · doi:10.1002/adbi.201800049 · Cited by 35 · see citing works

Ion Channel Drug Discovery

Gosling, M., & Cox, B. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781849735087 · Cited by 26 · see citing works

Identification of Ras-degrading small molecules that inhibit the transformation of colorectal cancer cells independent of β-catenin signaling

Shin, W., Lee, S.-K., Hwang, J.-H., Park, J.-C., Cho, Y.-H., Ro, E. J., Song, Y., Seo, H. R., & Choi, K.-Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0102-5 · Cited by 10 · see citing works

Untitled work

Magnusson (1999) · doi:10.1002/(sici)1097-0215(19990505)81:3

The current state of the art and future trends in RAS-targeted cancer therapies

Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549 · see citing works

Double-mismatched siRNAs enhance selective gene silencing of a mutant ALS-causing allele

Changming, Geng, G., HongLiu, et al. (2008) · 中国药理学报：英文版

High potency silencing by single-stranded boranophosphate siRNA

Hall, A., Wan, J., Spesock, A., Sergueeva, Z. A., Shaw, B. R., & Alexander, K. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl339 · Cited by 110 · see citing works

Enhanced gene silencing by the application of multiple specific small interfering RNAs

Ji, J., Wernli, M., Klimkait, T., et al. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00893-7 · Cited by 66 · see citing works

Mechanistic Insights into LDL Nanoparticle-Mediated siRNA Delivery

Jin, H., Lovell, J. F., Chen, J., Lin, Q., Ding, L., Ng, K. K., Pandey, R. K., Manoharan, M., Zhang, Z., & Zheng, G. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200233n · Cited by 52 · see citing works

Gene Silencing Activity of siRNA Molecules Containing Phosphorodithioate Substitutions

Yang, X., Sierant, M., Janicka, M., Pęczek, Ł., Martinez, C., Hassell, T., Li, N., Li, X., Wang, T., & Nawrot, B. (2012) · ACS Chemical Biology · doi:10.1021/cb300078e · Cited by 58 · see citing works